These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 28840314)

  • 61. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
    J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neuromyelitis Optica Spectrum Disorder and Anti-Aquaporin 4 Channel Immunoglobulin in an Australian Pediatric Demyelination Cohort.
    Dahan A; Brilot F; Leventer R; Kornberg AJ; Dale RC; Yiu EM
    J Child Neurol; 2020 Mar; 35(4):291-296. PubMed ID: 31896291
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
    Siritho S; Sato DK; Kaneko K; Fujihara K; Prayoonwiwat N
    Mult Scler; 2016 Jun; 22(7):964-8. PubMed ID: 26498263
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 66. Devic's index case: A critical reappraisal - AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?
    Jarius S; Wildemann B
    J Neurol Sci; 2019 Dec; 407():116396. PubMed ID: 31726278
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.
    Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927
    [TBL] [Abstract][Full Text] [Related]  

  • 72. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
    Carnero Contentti E; Lopez PA; Pettinicchi JP; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Tkachuk V; Liwacki S; Correale J; Marrodan M; Gaitán MI; Fiol M; Negrotto L; Ysrraelit MC; Burgos M; Leguizamon F; Tavolini D; Deri N; Balbuena ME; Mainella C; Luetic G; Blaya P; Hryb J; Menichini ML; Alvez Pinheiro A; Nofal P; Zanga G; Barboza A; Martos I; Lazaro L; Alonso R; Silva E; Bestoso S; Fracaro ME; Carrá A; Garcea O; Fernandez Liguori N; Alonso Serena M; Caride A; Rojas JI
    Mult Scler Relat Disord; 2021 Apr; 49():102742. PubMed ID: 33454601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J
    Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
    Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
    Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination.
    Li X; Wang L; Zhou L; ZhangBao J; Miao MZ; Lu C; Lu J; Quan C
    Mult Scler Relat Disord; 2019 Nov; 36():101397. PubMed ID: 31546225
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
    Redenbaugh V; Flanagan EP
    Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Double-negative neuromyelitis optica spectrum disorder.
    Wu Y; Geraldes R; Juryńczyk M; Palace J
    Mult Scler; 2023 Oct; 29(11-12):1353-1362. PubMed ID: 37740717
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.